Status:
NOT_YET_RECRUITING
Atrial Fibrillation: In Search for the Optimal Target for Rate Control
Lead Sponsor:
The University of Hong Kong
Conditions:
Atrial Fibrillation (Permanent)
Atrial Fibrillation (AF)
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A rate control strategy is commonly adopted in the management of patients with Atrial Fibrillation (AF). Controversies remain as regards to what constitutes the optimal target of rate control. Curren...
Eligibility Criteria
Inclusion
- Age of 18 years or above
- History of persistent or permanent AF (valvular or non-valvular). Persistent AF refers to sustained AF beyond 7 days. Permanent AF is defined as uninterrupted AF with duration of \>1 year with nil plan of restoration of sinus rhythm
- A 12-leads electrocardiogram (ECG) at baseline with documented heart rate \>/= 80 bpm
- Acceptance of rate control as the main management strategy, taking into consideration of recent clinical evidence, patient conditions and preference, as decided by clinical assessment prior to randomization
- Provision of informed consent
Exclusion
- Patients aged under 18 years
- Patients who were pregnant
- Those who were not in persistent or permanent AF
- Baseline heart rate \<80bpm on ECG
- Pre-existing high grade atrioventricular block, or medically unfit for heart rate reduction as assessed by attending clinician prior to randomization
- Hemodynamic instability, including those who require electrical cardioversion
- Known hypersensitivity to ivabradine or medication components
- Patients who do not accept rate control as mainstay of treatment strategy
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07135258
Start Date
October 1 2025
End Date
October 1 2027
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong